Brokerages Set Kenvue Inc. (NYSE:KVUE) Price Target at $20.23

Shares of Kenvue Inc. (NYSE:KVUE) have received a consensus rating of “Hold” from the eighteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Thirteen research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $19.90.

Several equities analysts have commented on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. JPMorgan Chase & Co. decreased their price objective on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and cut their target price for the stock from $23.00 to $18.00 in a research note on Friday. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Finally, Citigroup reduced their price objective on Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, October 9th.

Kenvue Trading Up 1.2%

Shares of KVUE stock opened at $17.41 on Thursday. The stock has a market cap of $33.36 billion, a P/E ratio of 23.21 and a beta of 0.60. Kenvue has a 1 year low of $14.02 and a 1 year high of $25.17. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a 50 day simple moving average of $17.16 and a 200 day simple moving average of $18.01.

Kenvue (NYSE:KVUE) last released its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. During the same period in the prior year, the company posted $0.28 EPS. The company’s revenue was down 3.5% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts predict that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th will be paid a $0.2075 dividend. The ex-dividend date of this dividend is Wednesday, February 11th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s dividend payout ratio is presently 110.67%.

Insider Buying and Selling at Kenvue

In related news, Director Jeffrey C. Smith purchased 3,200,000 shares of the stock in a transaction dated Friday, December 12th. The stock was bought at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the acquisition, the director owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.68% of the company’s stock.

Hedge Funds Weigh In On Kenvue

A number of institutional investors and hedge funds have recently bought and sold shares of KVUE. Salomon & Ludwin LLC bought a new position in Kenvue in the 3rd quarter valued at approximately $25,000. NBT Bank N A NY increased its position in Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after acquiring an additional 1,006 shares during the period. Cornerstone Planning Group LLC raised its stake in shares of Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after acquiring an additional 1,361 shares during the last quarter. Physician Wealth Advisors Inc. lifted its holdings in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the period. Finally, Golden State Wealth Management LLC grew its stake in shares of Kenvue by 150.1% in the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after purchasing an additional 1,190 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.